Literature DB >> 15651980

Role of the ERC motif in the proximal part of the second intracellular loop and the C-terminal domain of the human prostaglandin F2alpha receptor (hFP-R) in G-protein coupling control.

Andrea Pathe-Neuschäfer-Rube1, Frank Neuschäfer-Rube, Gerhard P Püschel.   

Abstract

The human FP-R (F2alpha prostaglandin receptor) is a Gq-coupled heptahelical ectoreceptor, which is of significant medical interest, since it is a potential target for the treatment of glaucoma and preterm labour. On agonist exposure, it mediates an increase in intracellular inositol phosphate formation. Little is known about the structures that govern the agonist-dependent receptor activation. In other prostanoid receptors, the C-terminal domain has been inferred in the control of agonist-dependent receptor activation. A DRY motif at the beginning of the second intracellular loop is highly conserved throughout the G-protein-coupled receptor family and appears to be crucial for controlling agonist-dependent receptor activation. It is replaced by an ERC motif in the FP-R and no evidence for the relevance of this motif in ligand-dependent activation of prostanoid receptors has been provided so far. The aim of the present study was to elucidate the potential role of the C-terminal domain and the ERC motif in agonist-controlled intracellular signalling in FP-R mutants generated by site-directed mutagenesis. It was found that substitution of the acidic Glu(132) in the ERC motif by a threonine residue led to full constitutive activation, whereas truncation of the receptor's C-terminal domain led to partial constitutive activation of all three intracellular signal pathways that had previously been shown to be activated by the FP-R, i.e. inositol trisphosphate formation, focal adhesion kinase activation and T-cell factor signalling. Inositol trisphosphate formation and focal adhesion kinase phosphorylation were further enhanced by ligand binding in cells expressing the truncation mutant but not the E132T (Glu132-->Thr) mutant. Thus C-terminal truncation appeared to result in a receptor with partial constitutive activation, whereas substitution of Glu132 by threonine apparently resulted in a receptor with full constitutive activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15651980      PMCID: PMC1186721          DOI: 10.1042/BJ20041321

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay.

Authors:  C Parnot; S Bardin; S Miserey-Lenkei; D Guedin; P Corvol; E Clauser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  FP prostanoid receptor activation of a T-cell factor/beta -catenin signaling pathway.

Authors:  H Fujino; J W Regan
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

Review 3.  Lessons from constitutively active mutants of G protein-coupled receptors.

Authors:  Charles Parnot; Stéphanie Miserey-Lenkei; Sabine Bardin; Pierre Corvol; Eric Clauser
Journal:  Trends Endocrinol Metab       Date:  2002-10       Impact factor: 12.015

4.  Differential regulation of prostaglandin F(2alpha) receptor isoforms by protein kinase C.

Authors:  H Fujino; D Srinivasan; K L Pierce; J W Regan
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

5.  Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton.

Authors:  K L Pierce; H Fujino; D Srinivasan; J W Regan
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

6.  Phenylalanine 138 in the second intracellular loop of human thromboxane receptor is critical for receptor-G-protein coupling.

Authors:  H Zhou; F Yan; S Yamamoto; H H Tai
Journal:  Biochem Biophys Res Commun       Date:  1999-10-14       Impact factor: 3.575

Review 7.  Effects of prostaglandins on the aqueous humor outflow pathways.

Authors:  Robert N Weinreb; Carol B Toris; B'Ann T Gabelt; James D Lindsey; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2002-08       Impact factor: 6.048

8.  Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors.

Authors:  Duane A Chung; Susan M Wade; Carol B Fowler; Danielle D Woods; Paolo B Abada; Henry I Mosberg; Richard R Neubig
Journal:  Biochem Biophys Res Commun       Date:  2002-05-17       Impact factor: 3.575

9.  Differential internalization of the prostaglandin f(2alpha) receptor isoforms: role of protein kinase C and clathrin.

Authors:  Dinesh Srinivasan; Hiromichi Fujino; John W Regan
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

10.  Interaction of Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides a mechanism for beta -catenin release.

Authors:  T E Meigs; T A Fields; D D McKee; P J Casey
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  3 in total

1.  Candidate chemoreceptor subfamilies differentially expressed in the chemosensory organs of the mollusc Aplysia.

Authors:  Scott F Cummins; Dirk Erpenbeck; Zhihua Zou; Charles Claudianos; Leonid L Moroz; Gregg T Nagle; Bernard M Degnan
Journal:  BMC Biol       Date:  2009-06-04       Impact factor: 7.431

Review 2.  Gα12 and Gα13: Versatility in Physiology and Pathology.

Authors:  Paipai Guo; Yu Tai; Manman Wang; Hanfei Sun; Lingling Zhang; Wei Wei; Yang K Xiang; Qingtong Wang
Journal:  Front Cell Dev Biol       Date:  2022-02-14

3.  Full and partial agonists of thromboxane prostanoid receptor unveil fine tuning of receptor superactive conformation and G protein activation.

Authors:  Valérie Capra; Marta Busnelli; Alessandro Perenna; Manuela Ambrosio; Maria Rosa Accomazzo; Celine Galés; Bice Chini; G Enrico Rovati
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.